reSET-O is the first FDA-approved prescription digital therapeutic for the treatment of patients with opioid use disorder in combination with usual treatment (e.g., buprenorphine). It is a 12-week (84-day) software application intended to increase retention of patients with opioid use disorder in outpatient treatment by providing cognitive behavioral therapy as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management for adult patients who are currently under the supervision of a clinician. A study found that this digital therapeutic may result in a minimal budget impact. The results of the study were presented during AMCP eLearning Days in a poster presentation titled “Budget Impact Analysis of reSET-O, an FDA-Cleared Prescription Digital Therapeutic for Patients with Opioid Use Disorder.”
Researchers created a hypothetical health care plan with one million lives to assess the per-member, per-month (PMPM) budget impact of the prescription digital therapeutic. They compared costs between a “current market” where the prescription digital therapeutic plus treatment as usual is not available with a “new market” in which the prescription digital therapeutic is available at market uptakes between 10% and 50%. Treatment as usual rates and real-world health care costs for adherent ($3,887) and non-adherent ($11,291) patients were estimated using the Truven MarketScan Commercial and Medicare Supplementary Database.
Twelve-week opioid use disorder treatment costs were calculated from individual component costs and included the following: reSET-O: 1 × $1,500; office visits 6 × $33; urinalyses: 36 × $70; and buprenorphine: 3 × $123.
Among a cohort of adult beneficiaries, 0.01% were identified as treated with treatment as usual (109 members per million). A budget impact analysis showed that downstream reductions in medical costs of $1,195 per patient treated with the addition of the prescription digital therapeutic offset the majority of the prescription digital therapeutic costs. Incremental per-patient costs for the new market ranged from $3,323 (10% market share) to $16,616 (50% market share), representing a budget impact between $0.001 to $0.006 PMPM, respectively.
The study was sponsored by Pear Therapeutics and Sandoz.
Velez F, Wang W, Gellings Lowe N, Jalali A, Murphy S. Budget Impact Analysis of reSET-O, an FDA-Cleared Prescription Digital Therapeutic for Patients with Opioid Use Disorder. Abstract F2. Presented during AMCP eLearning Days, April 20-24.